EARNEST Partners’s Juno Therapeutics, Inc. JUNO Stock Holding History

EARNEST Partners’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-16	Closed	-$1K	–	1226
2017 Q4	$1K	Buy	+16	New	+$798	﹤0.01%	1185
2017 Q1	–	Sell	-16	Closed	–	–	1108
2016 Q4	$0	Buy	+16	New	+$391	﹤0.01%	1185

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

EARNEST Partners's JUNO Position: Q1 2018 in Review

EARNEST Partners sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 16 shares — an estimated $1K sold.

EARNEST Partners first reported a position in JUNO in Q4 2016 and held it in 2 quarters. The position peaked at $1K in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

EARNEST Partners reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
EARNEST Partners sold 16 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $1K.
EARNEST Partners first reported a position in Juno Therapeutics, Inc. in Q4 2016 and held it in 2 quarters.
EARNEST Partners's Juno Therapeutics, Inc. position peaked at $1K in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on EARNEST Partners's 13F filing for Q1 2018, filed 15 May 2018.